Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters
Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters
Comments